These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26076798)

  • 41. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
    Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
    J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.
    Brink M; Meeuwes FO; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer LH; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Plattel W; Huls GA; Vermaat JSP; Nijland M
    Blood; 2022 Sep; 140(9):1009-1019. PubMed ID: 35544601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Controversies in the treatment of lymphoma with autologous transplantation.
    Moskowitz AJ; Moskowitz CH
    Oncologist; 2009 Sep; 14(9):921-9. PubMed ID: 19737999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of Peripheral T-cell Lymphomas and the Role of Transplant.
    Foley NC; Mehta-Shah N
    Curr Oncol Rep; 2022 Nov; 24(11):1489-1499. PubMed ID: 35947286
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.
    Dreger P; Laport GG
    Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):100-7. PubMed ID: 18162229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
    Simon A; Peoch M; Casassus P; Deconinck E; Colombat P; Desablens B; Tournilhac O; Eghbali H; Foussard C; Jaubert J; Vilque JP; Rossi JF; Lucas V; Delwail V; Thyss A; Maloisel F; Milpied N; le Gouill S; Lamy T; Gressin R
    Br J Haematol; 2010 Oct; 151(2):159-66. PubMed ID: 20738307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.
    Mehta N; Maragulia JC; Moskowitz A; Hamlin PA; Lunning MA; Moskowitz CH; Zelenetz A; Matasar MJ; Sauter C; Goldberg J; Horwitz SM
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):664-70. PubMed ID: 24035712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
    Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of Peripheral T-Cell Lymphoma: Many Shades of Gray.
    Lunning MA
    Oncology (Williston Park); 2015 Aug; 29(8):545-50. PubMed ID: 26281838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
    Alduaij A; Butera JN; Treaba D; Castillo J
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):480-3. PubMed ID: 21156467
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
    García-Sancho AM; Bellei M; López-Parra M; Gritti G; Cortés M; Novelli S; Panizo C; Petrucci L; Gutiérrez A; Dlouhy I; Bastos-Oreiro M; Sancho JM; Ramírez MJ; Moraleda JM; Carrillo E; Jiménez-Ubieto AI; Jarque I; Orsucci L; García-Torres E; Montalbán C; Dodero A; Arranz R; De Las Heras N; Pascual MJ; López-Jiménez J; Spina M; Re A; De Villambrosia SG; Bobillo S; Federico M; Caballero D
    Haematologica; 2022 Nov; 107(11):2675-2684. PubMed ID: 35320921
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The aggressive peripheral T-cell lymphomas: 2013.
    Armitage JO
    Am J Hematol; 2013 Oct; 88(10):910-8. PubMed ID: 24078271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stem cell transplantation for peripheral T-cell lymphomas.
    Jantunen E; D'Amore F
    Leuk Lymphoma; 2004 Mar; 45(3):441-6. PubMed ID: 15160904
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.
    Freedman AS; Neuberg D; Gribben JG; Mauch P; Soiffer RJ; Fisher DC; Anderson KC; Andersen N; Schlossman R; Kroon M; Ritz J; Aster J; Nadler LM
    J Clin Oncol; 1998 Jan; 16(1):13-8. PubMed ID: 9440717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
    Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.
    Rodríguez J; Conde E; Gutiérrez A; Lahuerta JJ; Arranz R; Sureda A; Zuazu J; Fernández de Sevilla A; Bendandi M; Solano C; León A; Varela MR; Caballero MD;
    Haematologica; 2007 Aug; 92(8):1067-74. PubMed ID: 17640855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
    Ludvigsen Al-Mashhadi A; Cederleuf H; Kuhr Jensen R; Holm Nielsen T; Bjerregård Pedersen M; Bech Mortensen T; Relander T; Jerkeman M; Ortved Gang A; Kristensen AL; Roost Clausen M; de Nully Brown P; Tang Severinsen M; Jakobsen LH; Ellin F; El-Galaly TC
    Am J Hematol; 2023 Mar; 98(3):388-397. PubMed ID: 36588403
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.